AHA to Sanofi U.S./Sanofi Genzyme Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs

AHA to Sanofi U.S./Sanofi Genzyme Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs to Hospitals and Health Systems

AHA expresses profound concern about actions Sanofi U.S./Sanofi Genzyme are taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.

Key Resources

Related Resources

Advancing Health Podcast
Addressing Mental Health Disparities Among Racial and Ethnic Minorities
Public
Letter/Comment
AHA Letter to CMS on The Increasing Organ Transplant Access (IOTA) Model
Public
AHA Center for Health Innovation Market Scan
4 Steps to Deliver Real-Time Health Data at the Point of Care
AHA Center for Health Innovation Market Scan
Work Remains, but Physician Burnout Rates Are Coming Down
Letter/Comment
AHA Comment Letter on the Senate Pay PCPs Act (S. 4338)
Public
Advancing Health Podcast
How a Rural Health System Continues to Provide Essential Obstetric Services
Public